These preclinical experiments and clinical practices as well as data from other tumors point to the importance of exploring the combination immunotherapy with rationale mechanisms [15, 36], in this regard, our previous studies demonstrate that concomitant checkpoint blockade and costimulatory molecule triggering, such as combined α-PD-1/α-OX40 or α-TIM3/CD137 mAb, produced a highly synergistic antitumor efficacy in ID8 tumor [25, 26]. Here, TNFRSF9 is linked to neoplasm.